AbbVie executives have expressed optimism over the performance of its new medications Skyrizi and Rinvoq, which are gaining traction in the market despite concerns about competition from Humira. The company’s CEO Rob Michael has assured that AbbVie is thriving, following a period of uncertainty surrounding Humira’s patent expiration.
Source: https://endpts.com/abbvie-executives-bask-in-skyrizi-rinvoq-successes-as-the-drugs-take-up-humiras-mantle